WiSEED
VC Fund
Toulouse, France
Wiseed is a crowdfunding platform that enables its users to invest in SMEs and enterprises. The platform offers investments for startups, real-estate firms, social innovation and renewable energy projects, and agriculture firms. It was founded in 2008 by Nicolas Seres and Thomas Merquiol and is based in Toulouse.
- Total investments:
- 34
- Last investment:
- Lead investor:
- 29%
Last updated:
For AI agents: llms.txt
Industries WiSEED invests in
Stages WiSEED invests in
Countries WiSEED invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $392k–$3.3M
- Series A
- $1.3M–$7.8M
- Venture - Series Unknown
- $1M–$6.5M
Investment Focus
Industry
- Software 7 (21%)
- Biotechnology 7 (21%)
- Manufacturing 6 (18%)
- SaaS 4 (12%)
- Medical Device 4 (12%)
Stage
- Seed 14 (41%)
- Venture - Series Unknown 9 (26%)
- Series A 3 (9%)
- Equity Crowdfunding 3 (9%)
- Funding Round 2 (6%)
Country
- France 28 (82%)
- Norway 1 (3%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Nicolas SÉRÈS
Co-Founder & CEO
|
Co-Founder & CEO | Total investments: 1 | Find email | |
Stephanie SAVEL
President
|
President | Total investments: 0 | Find email | |
Thierry MERQUIOL
Co-Founder & Chairman of the board
|
Co-Founder & Chairman of the board | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| The Aéronde is an innovative electric airship with a toroidal shape (giant donut) of 15 meters in diameter, designed to offer a silent, energy-efficient flight with very low environmental impact. Inflated with approximately 400 m³ of helium, it can carry up to two people and equipment, with a payload of 200 kg . | $1.1M / Seed / May 05, 2025 | ||
| BiPER Therapeutics is a biotech company to develop and commercializes novel therapeutics. | $839.6K / Debt Financing / Dec 17, 2024 | ||
| Vaxinano is a biotechnology company specialized in preclinical and pharmaceutical development of human and veterinary vaccines and drug delivery systems. Vaxinano was created in 2016, building on 25 years of research and clinical trials on vaccines and the patented technology of Pr Didier Betbeder. | $6.5M / Venture - Series Unknown / Oct 29, 2024 | ||
| Leasi delivers a forward-thinking rental and resource management system for companies that engage in internal or external distribution of machinery. This is achieved through an ecosystem that emphasizes the excessive use of data and datasharing, with a focus on user experience. Our goal is to create a simpler, more streamlined, and more efficientworkday for industry players by leveraging the power of data and collaboration within the ecosystem to ultimately reduce emissions, increase efficiency and enhance profitability. | $1.2M / Pre-Seed / Jul 01, 2024 | ||
| BiPER Therapeutics is a biotech company to develop and commercializes novel therapeutics. | $322.1K / Seed / Feb 14, 2023 | ||
| Dianosic was founded in 2017 and develops innovative solutions in the field of ENT (Ear, Nose & Throat), a $50 billion, double digit growth, and still largely underserved market. Our startup operates right at the frontier between Medtech and Biotech, as we see tremendous opportunities for drug-device combinations in this specialty. The projectoriginates from the ENT Department from the University Hospital of Strasbourg, where unmet clinical needs have been identified. Our main focus areas are Chronic Rhinitis, Chronic Sinusitis and intranasal bleeding (Epistaxis). Noteworthy, Dianosic has a strong French and German footprint in R&D and manufacturing.Dianosic’s strategic goal is to establish new standards of care in Chronic Rhinitis and Chronic Sinusitis with its drug-eluting Active Resorbable Scaffold (ARIS). This drug-device combination ARIS platform, developed with world renowned resorbable polymers experts, has the potential to establish new treatment paradigms. Moreover, our ARIS platform creates immense opportunities to create other verticals, especially in the field of chronic migraine and facial pain.Beside this, Dianosic commercialize an Asymmetric Intranasal inflatable solution (CAVI-T) for the treatment of intranasal bleeding, a widespread condition in ENT that affects 10% of the population. This CE marked and FDA registered technology addresses a clear unmet need and demonstrated our ability not only to develop a differentiated technology in record time, but also to successfully transition from R&D to Sales. We are currently present in relevant markets in EU and paving the way to launch in the U.S. in the mid term. Noteworthy, since our main call point is the ENT, CAVI-T prepares the ground for our upcoming ARIS platform. | $5M / Seed / Feb 06, 2023 | ||
| Today 1 women on 8 has a breast cancer, 40% of them will have a mastectomy to cure cancer and only 14% of them will have reconstruction because actual technics does no fit for breast reconstruction. That’s why LATTICE MEDICAL develops the implantable device MATTISSE which answer to clinical and societal issues and allow women to get back theirbodies and life. MATTISSE implant allows a natural reconstruction by regenerating autologous adipose tissues, custom reconstruction thanks to 3D printing and single surgery due to fully biodegradable material, which fully disappear after reconstruction. We aim in long term to replace silicon-based implant by our technology. | $7.8M / Series A / Oct 01, 2022 | ||
| VistaCare is an innovative French VSE specializing in medical devices. They develop, manufacture, and distribute medical devices for the treatment of the critical phase of acute and chronic wounds. The company's technology enhances the quality of life and the care pathway for patients with wounds, as well as simplifying the daily lives ofcaregivers by drastically lowering treatment times and hospital stays. | $4.5M / Venture - Series Unknown / Jan 20, 2022 | ||
| BioIntrant provides agricultural productivity improving services. They also provide biotechnology, agriculture, agronomy, microbiology, biostimulator, bioinformatics, and genomics services. | $1.7M / Seed / Jan 20, 2022 | ||
| SPARTHA Medical develops invisible, eco-friendly, personalized and biocompatible coatings addressed to medical devices and consumer products to protect users from microbial and inflammatory risks.Our innovation stands on natural biopolymers which supramolecular assembly confers antibacterial, antiviral and anti-inflammatory properties to anysurface. We work basically with two different polyelectrolytes that do not need any further chemical procedure than mix to be effective. We can control the way they assemble (patented technology) to confer the versatile and multifunctional property we want to address depending on the field of work. | $1.6M / Seed / Dec 08, 2021 | ||
| See all 34 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does WiSEED invest in?
WiSEED invests primarily in Software, Biotechnology and Manufacturing startups, most often at Seed and Venture - Series Unknown stage. Most of the 34 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is WiSEED's check size?
WiSEED typically joins rounds of $392k–$3.3M at Seed, $1.3M–$7.8M at Series A and $1M–$6.5M at Venture - Series Unknown. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds WiSEED participates in.
How do I contact WiSEED?
Public channels for WiSEED include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at WiSEED?
The team at WiSEED includes Nicolas SÉRÈS (Co-Founder & CEO), Stephanie SAVEL (President) and Thierry MERQUIOL (Co-Founder & Chairman of the board). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
